146 related articles for article (PubMed ID: 8815000)
1. Effect of antisense inhibition of Urokinase receptor on malignancy.
Ossowski L
Curr Top Microbiol Immunol; 1996; 213 ( Pt 3)():101-12. PubMed ID: 8815000
[No Abstract] [Full Text] [Related]
2. Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
Yang JL; Seetoo Dq; Wang Y; Ranson M; Berney CR; Ham JM; Russell PJ; Crowe PJ
Int J Cancer; 2000 Sep; 89(5):431-9. PubMed ID: 11008205
[TBL] [Abstract][Full Text] [Related]
3. Urokinase type plasminogen activator and its receptor regulate the invasive potential of gastric cancer cell lines.
Okusa Y; Ichikura T; Mochizuki H; Shinomiya N
Int J Oncol; 2000 Nov; 17(5):1001-5. PubMed ID: 11029504
[TBL] [Abstract][Full Text] [Related]
4. Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion.
Rømer J; Pyke C; Lund LR; Eriksen J; Kristensen P; Rønne E; Høyer-Hansen G; Danø K; Brünner N
Int J Cancer; 1994 May; 57(4):553-60. PubMed ID: 8181859
[TBL] [Abstract][Full Text] [Related]
5. Molecular regulation of urokinase-receptor gene expression as one potential concept for molecular staging and therapy.
Allgayer H
Recent Results Cancer Res; 2003; 162():15-30. PubMed ID: 12790318
[TBL] [Abstract][Full Text] [Related]
6. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy.
Kook YH; Adamski J; Zelent A; Ossowski L
EMBO J; 1994 Sep; 13(17):3983-91. PubMed ID: 8076594
[TBL] [Abstract][Full Text] [Related]
7. Antisense oligonucleotides against the urokinase receptor: a therapeutic strategy for the control of cell invasion in rheumatoid arthritis and cancer.
Del Rosso M; Fibbi G; Pucci M; Cerinic MM
Clin Exp Rheumatol; 1998; 16(4):389-93. PubMed ID: 9706415
[No Abstract] [Full Text] [Related]
8. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS
Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth.
Mohan PM; Chintala SK; Mohanam S; Gladson CL; Kim ES; Gokaslan ZL; Lakka SS; Roth JA; Fang B; Sawaya R; Kyritsis AP; Rao JS
Cancer Res; 1999 Jul; 59(14):3369-73. PubMed ID: 10416596
[TBL] [Abstract][Full Text] [Related]
10. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells.
Nip J; Rabbani SA; Shibata HR; Brodt P
J Clin Invest; 1995 May; 95(5):2096-103. PubMed ID: 7537755
[TBL] [Abstract][Full Text] [Related]
11. Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy?
Fazioli F; Blasi F
Trends Pharmacol Sci; 1994 Jan; 15(1):25-9. PubMed ID: 8140655
[TBL] [Abstract][Full Text] [Related]
12. Suppression of glioma invasion and growth by adenovirus-mediated delivery of a bicistronic construct containing antisense uPAR and sense p16 gene sequences.
Adachi Y; Chandrasekar N; Kin Y; Lakka SS; Mohanam S; Yanamandra N; Mohan PM; Fuller GN; Fang B; Fueyo J; Dinh DH; Olivero WC; Tamiya T; Ohmoto T; Kyritsis AP; Rao JS
Oncogene; 2002 Jan; 21(1):87-95. PubMed ID: 11791179
[TBL] [Abstract][Full Text] [Related]
13. Targeting urokinase-type plasminogen activator and its receptor for cancer therapy.
Nozaki S; Endo Y; Nakahara H; Yoshizawa K; Ohara T; Yamamoto E
Anticancer Drugs; 2006 Nov; 17(10):1109-17. PubMed ID: 17075310
[TBL] [Abstract][Full Text] [Related]
14. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness.
Blasi F
Bioessays; 1993 Feb; 15(2):105-11. PubMed ID: 8385942
[TBL] [Abstract][Full Text] [Related]
15. Urokinase-dependent angiogenesis in vitro and diacylglycerol production are blocked by antisense oligonucleotides against the urokinase receptor.
Fibbi G; Caldini R; Chevanne M; Pucci M; Schiavone N; Morbidelli L; Parenti A; Granger HJ; Del Rosso M; Ziche M
Lab Invest; 1998 Sep; 78(9):1109-19. PubMed ID: 9759655
[TBL] [Abstract][Full Text] [Related]
16. [Experimental study of anti-metastasis effect of urokinase amino-terminal fragment gene on human breast cancer cells].
Zhu F; Xing G; He F
Zhonghua Zhong Liu Za Zhi; 2001 Mar; 23(2):115-7. PubMed ID: 11783013
[TBL] [Abstract][Full Text] [Related]
17. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.
Choong PF; Nadesapillai AP
Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S46-58. PubMed ID: 14600592
[TBL] [Abstract][Full Text] [Related]
18. Role of urokinase, its receptor, and serpins in colorectal carcinoma.
Jessup JM
Gastroenterology; 1994 Nov; 107(5):1555-9. PubMed ID: 7926521
[No Abstract] [Full Text] [Related]
19. In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor.
Mohanam S; Chintala SK; Go Y; Bhattacharya A; Venkaiah B; Boyd D; Gokaslan ZL; Sawaya R; Rao JS
Oncogene; 1997 Mar; 14(11):1351-9. PubMed ID: 9178895
[TBL] [Abstract][Full Text] [Related]
20. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
Mamoune A; Kassis J; Kharait S; Kloeker S; Manos E; Jones DA; Wells A
Exp Cell Res; 2004 Sep; 299(1):91-100. PubMed ID: 15302576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
